What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Eric Dein ericdeinmd
3 years 6 months ago
PAISLEY LB004
@EricFMorand on deucravacitinib phase 2 for SLE
⭐️Meets primary endpt: SRI(4)
⭐️Secondary endpts: BICLA, LLD, CLASI, jt count, biomarkers improved
⭐️Safety data wo VTE, CVD events
Earlier at #EULAR2022, BRAVE trial phase 3 baricitinib: No benefit in SLE
@RheumNow https://t.co/3YpPSJcenF
Dr. Antoni Chan synovialjoints
3 years 6 months ago
Wetterslev et al showed that almost all of 108 axSpA patients in clinical remission flared during tapering,47% flared at 2/3 to ½ dose and 53% at 1/3 to discontinuation. Higher baseline physician global score was an independent predictor of flare #EULAR2022 @RheumNow POS0298 https://t.co/RELuiB3Enl
Aurelie Najm AurelieRheumo
3 years 6 months ago
PAISLEY study Phase 2 RCT
Deucravacitinib in SLE meets primary endpoint wk 32
Results for dose 3mg BID:
*SRI(4) response 58.2% vs.
PBO 34%
*LLDAS 36%
*CLASI 70%
*⬇️ SJC
No new safety signal
Now waiting for Phase 3 👀
@RheumNow LB0004 #EULAR2022 #Lupus https://t.co/2KYSvfq4h7
Richard Conway RichardPAConway
3 years 6 months ago
Dr Coates @DrLauraCoates et al. Domains contributing to MDA achievement in guselkumab treated PsA. Physican assessed improved faster than patient assessed. Age, fatigue, BMI, baseline domain score determinants @RheumNow #EULAR2022 POS1067 https://t.co/vPsmeyPjzG
David Liew drdavidliew
3 years 6 months ago
Talking about tapering studies in inflammatory arthritis, but true throughout all of rheumatology:
Not all flares are equal.
This area is full of nuance, we need to think more closely about how we study them.
#EULAR2022 @RheumNow https://t.co/tzqqNZv5Ct
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#POS1112 #EULAR2022 A crossover RCT assessed effect of weight- and non-weight bearing exercises on type 2 collagen in knee #osteoarthritis. Small rise in collagen turnover markers initially for 24hrs. Gradual rise later on was contributed to cardiovascular influence @RheumNow https://t.co/AOxdFNihPR
Aurelie Najm AurelieRheumo
3 years 6 months ago
Shall we include US findings in CASPAR criteria? ⚡️
Adding US tenosynovitis
and/or enthesitis
- improves Specificity 91% vs. 68%
-while maintaining sensitivity 92% vs. 96%
#EULAR2022 @RheumNow POS0315 https://t.co/kuxPpVEQng
Richard Conway RichardPAConway
3 years 6 months ago
Dr Nash @drpnash Baseline determinants of pain response in IL23i guselkumab. Gus improved pain by week 2. Higher baseline pain, lower fatigue, lower TJC + predictors, NSAID use - predictor @RheumNow #EULAR2022 POS1070 https://t.co/4aNz9IQySj
David Liew drdavidliew
3 years 6 months ago
The potential for patients to benefit from digital health technologies in rheumatology is multifaceted, upside might be enormous.
There's so much space for us all, but there are factors in many domains where it can all go wrong.
We need to raise standards.
#EULAR2022 @RheumNow https://t.co/TozfK1Qs16
Janet Pope Janetbirdope
3 years 6 months ago
High markers at baseline of IL23 pathway better predict ACR20 response to #deucracitinib in #PsA #psoriatic arthritis. Analysis of RCT @eular_org @RheumNow #POS0005 Good proof of concept of TYK2 efficacy https://t.co/yyH5niUEEU
Richard Conway RichardPAConway
3 years 6 months ago
Therkildsen et al Ocular manifestations GCA in Denmark. Quite low proportion at 7%. Most occur around time diagnosis, with 1/3 pre-diagnosis. Aspirin not assoc reduced risk. @RheumNow #EULAR2022 POS0791 https://t.co/YgailfJ6fI
Dr. Antoni Chan synovialjoints
3 years 6 months ago
New in AS. Upadacitinib 15mg od was significantly more effective than placebo over 14 weeks in AS bDMARD-IR (ASAS40 45% vs 18% and the onset of effect seen by week 4), no new safety risks identified in the SELECT-AXIS 2 study by Van de Heijde et al #EULAR2022 @RheumNow POS0306 https://t.co/LCQBf38GWe
Aurelie Najm AurelieRheumo
3 years 6 months ago
CorEvitas PsA Registry (1000+ pts)
Analysis of biologics prescription according to disease domains
No real surprise to see that IL-17i were prescribed more frequently in pts w/ PsO BSA>10% at BL
Overall first line TNFi 40% > IL-17i 14%
POS0309 @RheumNow #EULAR2022 https://t.co/dkLxl8d6ug
David Liew drdavidliew
3 years 6 months ago
Everything's better with MTX
Controlled RA on b/tsDMARDs: can we taper MTX?
maintaining remission pooled OR 0.81 (0.68-0.97)
Unless I'm reading it wrong:
it's true many will be fine, but
keeping MTX adds benefit (even in short term, before ADAb)
POS0286 #EULAR2022 @RheumNow https://t.co/ZlwXHgACWd
Dr. John Cush RheumNow
3 years 6 months ago
SELECT-AXIS 1 trial of upadacitinib in active #AS with an inadequate resp to prior biologic - pivotal phase 2/3 RCT of 420 AS pts (Dz dur 7.7 yrs; 83% B27+) showed better ASAS40 at wk 14 w/ UPA vs PBO (45% vs 18%; P<0.0001) #EULAR2022 POS0306 https://t.co/6ZBEvjRjqc https://t.co/GL0vlB34mE
Poster Hall